In September 2025 , Eli Lilly and Company invested $6.5 billion to build a new manufacturing facility in Houston, Texas, dedicated to producing its experimental oral GLP-1 pill, orforglipron
Gallbladder Issues Research shows an increase in gallbladder-related issues in GLP-1 medication users, with conditions ranging from asymptomatic gallstones to severe cholecystitis requiring surgical intervention
Berg S, Stickle H, Rose SJ, Nemec EC
This is the same receptor that semaglutide targets , and it works by slowing gastric emptying, enhancing insulin secretion in response to glucose, and sending satiety signals to the brain
Retatrutide 20mg Vial
Thus, they consume fewer nutrients than they require to thrive long-term